Pharmaceutical Strategies Group (PSG) is pleased to present the 2023 Trends in Drug Benefit Design Report, which details traditional (non-specialty) drug benefit trends and strategies. This annual report, previously published under the Pharmacy Benefit Management Institute (PBMI) brand and first conducted in 1995, demonstrates PSG’s ongoing commitment to generating meaningful conversations and providing valuable insights about drug benefit design and management.
Here’s a sneak peek into some of the research results:
- Weight Loss Medications: With respondents divided on weight loss as a lifestyle or chronic condition, 43% cover FDA- approved weight loss medications and 28% may in the next 1-2 years.
- Utilization Management Programs: Growing percentages of respondents cite cost and cumbersomeness as barriers to utilization management programs.
- Gene Therapy Financial Protection Products: Most (91%) respondents have heard of gene therapy financial protection products. While just 7% currently use these products, nearly half are considering it.
- Formulary Management: A little over half of plans (53%) take steps to identify and reduce wasteful spend in the formulary.
- Cost Sharing: The promotion of cost-sharing transparency tools to help members manage expenses continues to rise, from 28% in 2018 to 63% in 2023.
